Pharmaceutical care of biotechnology: Distribution, pharmacoeconomics, product evaluation, and specialty practice considerations

Journal of Pharmacy Practice

Volumn 11, Issue 1, 1998, Pages 38-45

  Piascik, Peggy ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BIOLOGICAL FACTOR; HEPATITIS B VACCINE; INSULIN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STREPTOKINASE;

BIOTECHNOLOGY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG UTILIZATION; QUALITY CONTROL; REIMBURSEMENT; REVIEW;

EID: 0032459939     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/089719009801100107     Document Type: Review

References (12)

1. Szeinbach SL, and Gillenwater EL, "Biotechnology: The Challenges of Distribution," American Pharmacy NS35, 1995.
2. American Pharmaceutical Association "Biotech Rx: Opportunities in Therapy Management, Effective Patient Care: From Drug Therapy to Reimbursement," Executive Report #2, 1993.
3. Mehl B, and Santell JP, "Projecting future drug expenditures - 1997," American Journal of Health-System Pharmacy 54:153-161, 1997.
4. McIntyre WJ, and Johnson JT, "Biotechnology in Retail Pharmacy," American Druggist, August, 50-57, 1996.
5. Biotechnology Medicines in Development, 1996 Survey. Pharmaceutical Research and Manufacturers of American, May 1996.
6. Bootman JL, Townsend RJ, and McGhan WF, Principles of Pharmacoeconomics. Second edition. Cincinnati: Harvey Whitney, 1996.
7. Reeder CE, "Overview of pharmacoeconomics and pharmaceutical outcomes and evaluations," American Journal of Health-System Pharmacy 52:S5-S8, 1995.
8. Mark DB, Hlatky MA, Califf RM, et al. "Cost effectiveness of thrombolytic therapy for tissue plasminogen activator as compared with streptokinase for acute myocardial infarction," New England Journal of Medicine 332:1418-24, 1995.
9. Cahill NE, "Caveats in interpreting and applying pharmacoeconomic data," American Journal of Health-System Pharmacy 52:S24-S26, 1995.
10. Huber SL, "Strategic management of biotechnology agents," American Journal of Hospital Pharmacy 50:S31-33, 1993.
11. Tami J, and Evens RP, "Evaluation of Biotechnology Products," Pharmacotherapy 16:527-536, 1996.
12. Piascik P, "Should you add biotechnology to your practice?," American Pharmacy NS35:9-10, 1995.